The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis-Reference-Cited by-同舟云学术

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

Published:2018-11 Issue: Volume:131 Page:83-89
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Staropoli Nicoletta,Ciliberto Domenico,Del Giudice Teresa,Iuliano Eleonora,Cucè Maria,Grillone Francesco,Salvino Angela,Barbieri Vito,Russo Antonio^ORCID,Tassone Pierfrancesco,Tagliaferri Pierosandro

Funder

PhD program of Magna Graecia University: “molecular oncology and translational and innovative medical and surgical techniques”

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference57 articles.

1. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis;Arbitrio;Cancer Chemother. Pharmacol.,2016

2. DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine;Arbitrio;Oncotarget,2016

3. Assessment of study quality for systematic reviews: a comparison of the cochrane collaboration risk of Bias tool and the effective public health practice project quality assessment tool: methodological research;Armijo-Olivo;J. Eval. Clin. Pract.,2012

4. Two-tailed Fisher’s exact test (Cochran-Mantel-Haenzel);Balasubramaniam;Spine J.,2002

5. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer;Baudi;Hum. Mutat.,2001

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer;Gynecologic Oncology;2024-02

2. Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials;Expert Review of Anticancer Therapy;2024-01-25

3. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-01

4. PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials;Biomedical Research and Therapy;2023-12-31

5. Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges;Frontiers in Oncology;2023-09-06